Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANI PHARMACEUTICALS INCANIP · Entity 4638 | Director · President and CEO | April 06, 2020 | April 08, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANI PHARMACEUTICALS INC
Report date April 06, 2020 · Filed April 08, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 190,309 |
Ending reported balance
After 2020-04-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-04-06 · Tax withholding · Disposed 3,282 · Balance 192,424 F1: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 7,275 shares of restricted stock, which was previously reported. Row 2 · 2020-04-07 · Tax withholding · Disposed 2,115 · Balance 190,309 F2: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,688 shares of restricted stock, which was previously reported. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 7,275 shares of restricted stock, which was previously reported.
F2: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,688 shares of restricted stock, which was previously reported.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 07, 2020 Filed Apr 8, 2020 21:54 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 2,115 | $43.93 | $92,911.95 |
DisclosureSEC source: 0001104659-20-044729 · tm2015378d3_4.xml · nonDerivative · entry 2 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,309 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,688 shares of restricted stock, which was previously reported. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 21:54 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 3,282 | $43.22 | $141,848.04 |
DisclosureSEC source: 0001104659-20-044729 · tm2015378d3_4.xml · nonDerivative · entry 1 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,424 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 7,275 shares of restricted stock, which was previously reported. Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 01:37 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 2,679 | $40.74 | $109,142.46 |
DisclosureSEC source: 0001104659-20-041406 · tm2014433-1_4.xml · nonDerivative · entry 2 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,706 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 5,938 shares of restricted stock, which was previously reported. Read SEC document |
| March 28, 2020 Filed Apr 1, 2020 01:37 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 4,204 | $37.76 | $158,743.04 |
DisclosureSEC source: 0001104659-20-041406 · tm2014433-1_4.xml · nonDerivative · entry 1 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,385 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 9,320 shares of restricted stock, which was previously reported. Read SEC document |
| May 15, 2019 Filed May 15, 2019 21:16 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 14,633 | $69.25 | $1,013,335.25 |
DisclosureSEC source: 0001144204-19-026662 · tv521766_form4.xml · nonDerivative · entry 3 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,589 Read SEC document |
| May 14, 2019 Filed May 15, 2019 21:16 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 5,772 | $70.45 | $406,637.40 |
DisclosureSEC source: 0001144204-19-026662 · tv521766_form4.xml · nonDerivative · entry 2 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,222 Read SEC document |
| May 13, 2019 Filed May 15, 2019 21:16 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 9,595 | $71.10 | $682,204.50 |
DisclosureSEC source: 0001144204-19-026662 · tv521766_form4.xml · nonDerivative · entry 1 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,994 Read SEC document |
| April 16, 2019 Filed Apr 18, 2019 20:33 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 1,692 | $68.60 | $116,071.20 |
DisclosureSEC source: 0001144204-19-020282 · tv519119_form4.xml · nonDerivative · entry 1 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,589 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,750 shares of restricted stock, which was previously reported. Read SEC document |
| April 07, 2019 Filed Apr 9, 2019 20:41 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 2,115 | $70.50 | $149,107.50 |
DisclosureSEC source: 0001144204-19-018898 · tv518451_form4.xml · nonDerivative · entry 2 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,281 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,688 shares of restricted stock, which was previously reported. Read SEC document |
| April 06, 2019 Filed Apr 9, 2019 20:41 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 3,282 | $70.50 | $231,381.00 |
DisclosureSEC source: 0001144204-19-018898 · tv518451_form4.xml · nonDerivative · entry 1 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,396 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 7,275 shares of restricted stock, which was previously reported. Read SEC document |
| March 31, 2019 Filed Apr 2, 2019 20:45 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 2,678 | $70.54 | $188,906.12 |
DisclosureSEC source: 0001144204-19-017765 · tv517844_4.xml · nonDerivative · entry 1 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,678 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 5,937 shares of restricted stock, which was previously reported. Read SEC document |
| March 28, 2019 Filed Apr 1, 2019 20:01 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantStock Options · Derivative | 45,106 | $0.00 Strike: $66.39 | $0.00 |
DisclosureSEC source: 0001144204-19-017410 · tv517660_4.xml · derivative · entry 2 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,106 Underlying: Common Stock · 45,106 shares Expires 2029-03-27 F1 · security: The restricted stock and stock options vest in four equal annual installments on the first, second, third and fourth anniversary of March 28, 2019. F1 · derivative.exercise_date: The restricted stock and stock options vest in four equal annual installments on the first, second, third and fourth anniversary of March 28, 2019. Read SEC document |
| March 28, 2019 Filed Apr 1, 2019 20:01 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 37,280 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-017410 · tv517660_4.xml · nonDerivative · entry 1 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,356 F1 · security: The restricted stock and stock options vest in four equal annual installments on the first, second, third and fourth anniversary of March 28, 2019. Read SEC document |
| March 19, 2019 Filed Mar 20, 2019 20:07 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Exercise / conversionStock Options · Derivative | 2,823 | $0.00 Strike: $49.51 | $0.00 |
DisclosureSEC source: 0001144204-19-015117 · tv516671_form4.xml · derivative · entry 6 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,625 Underlying: Common Stock · 2,823 shares Expires 2027-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Option vests and are exercisable over a four year period beginning on the first anniversary of March 31, 2017. Read SEC document |
| March 19, 2019 Filed Mar 20, 2019 20:07 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 2,823 | $63.51 | $179,288.73 |
DisclosureSEC source: 0001144204-19-015117 · tv516671_form4.xml · nonDerivative · entry 2 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,076 F2 · price: The shares were sold in multiple trades at prices ranging from $63.49 to $63.60. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The reporting person owns 205,076 shares of the Issuer's common stock following the transaction, which is the same number of shares reported on his most recent prior filing. F2 · balance_after: The shares were sold in multiple trades at prices ranging from $63.49 to $63.60. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The reporting person owns 205,076 shares of the Issuer's common stock following the transaction, which is the same number of shares reported on his most recent prior filing. Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 20:07 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Exercise / conversionStock Options · Derivative | 9,052 | $0.00 Strike: $49.51 | $0.00 |
DisclosureSEC source: 0001144204-19-015117 · tv516671_form4.xml · derivative · entry 5 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,448 Underlying: Common Stock · 9,052 shares Expires 2027-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Option vests and are exercisable over a four year period beginning on the first anniversary of March 31, 2017. Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 20:07 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Exercise / conversionStock Options · Derivative | 9,375 | $0.00 Strike: $40.59 | $0.00 |
DisclosureSEC source: 0001144204-19-015117 · tv516671_form4.xml · derivative · entry 4 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 9,375 shares Expires 2026-04-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option vests and are exercisable over a four year period beginning on the first anniversary of April 7, 2016. Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 20:07 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Exercise / conversionStock Options · Derivative | 6,375 | $0.00 Strike: $33.00 | $0.00 |
DisclosureSEC source: 0001144204-19-015117 · tv516671_form4.xml · derivative · entry 3 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,375 shares Expires 2024-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option vests and are exercisable over a four year period beginning on the first anniversary of April 1, 2014. Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 20:07 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 24,802 | $63.53 | $1,575,671.06 |
DisclosureSEC source: 0001144204-19-015117 · tv516671_form4.xml · nonDerivative · entry 1 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,076 F1 · price: The shares were sold in multiple trades at prices ranging from $63.49 to $64.06. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The reporting person owns 205,076 shares of the Issuer's common stock following the transaction, which is the same number of shares reported on his most recent prior filing. F1 · balance_after: The shares were sold in multiple trades at prices ranging from $63.49 to $64.06. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The reporting person owns 205,076 shares of the Issuer's common stock following the transaction, which is the same number of shares reported on his most recent prior filing. Read SEC document |
| November 30, 2018 Filed Jan 2, 2019 22:24 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GiftCommon Stock | 2,180 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-000179 · tv510210_form5.xml · nonDerivative · entry 1 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,076 F1 · kind: The Reporting Person gifted the shares. No reconsideration was paid for the shares. F1 · price: The Reporting Person gifted the shares. No reconsideration was paid for the shares. Read SEC document |
| May 22, 2018 Filed May 24, 2018 20:02 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 1,375 | $61.88 | $85,085.00 |
DisclosureSEC source: 0001144204-18-030788 · tv494958_form4.xml · nonDerivative · entry 1 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,256 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of restricted stock, which was previously reported. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 20:36 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 1,611 | $60.21 | $96,998.31 |
DisclosureSEC source: 0001144204-18-021177 · tv491303_4.xml · nonDerivative · entry 1 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,631 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of restricted stock, which was previously reported. Read SEC document |
| April 07, 2018 Filed Apr 10, 2018 21:23 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 2,014 | $57.06 | $114,918.84 |
DisclosureSEC source: 0001144204-18-019986 · tv490742_4.xml · nonDerivative · entry 2 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,242 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of restricted stock, which was previously reported. Read SEC document |
| April 06, 2018 Filed Apr 10, 2018 21:23 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantStock Options · Derivative | 35,200 | $0.00 Strike: $57.06 | $0.00 |
DisclosureSEC source: 0001144204-18-019986 · tv490742_4.xml · derivative · entry 3 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,200 Underlying: Common Stock · 35,200 shares Expires 2028-04-05 F1 · security: The restricted stock and the stock options vests, and are exercisable, in equal annual installments on the first, second, third and fourth anniversaries of the grant date. F1 · derivative.exercise_date: The restricted stock and the stock options vests, and are exercisable, in equal annual installments on the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| April 06, 2018 Filed Apr 10, 2018 21:23 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 29,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-019986 · tv490742_4.xml · nonDerivative · entry 1 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,256 F1 · security: The restricted stock and the stock options vests, and are exercisable, in equal annual installments on the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| March 31, 2018 Filed Apr 3, 2018 21:19 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 2,550 | $58.22 | $148,461.00 |
DisclosureSEC source: 0001144204-18-019005 · tv490182_form4.xml · nonDerivative · entry 1 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,156 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of restricted stock, which was previously reported. Read SEC document |
| March 14, 2018 Filed Mar 14, 2018 23:02 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 10,000 | $62.03 | $620,300.00 |
DisclosureSEC source: 0001144204-18-014729 · tv488500_form4.xml · nonDerivative · entry 4 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,706 F3 · price: This transaction was executed in multiple trades at prices ranging from $62.00 to $62.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 13, 2018 Filed Mar 14, 2018 23:02 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 6,525 | $62.63 | $408,660.75 |
DisclosureSEC source: 0001144204-18-014729 · tv488500_form4.xml · nonDerivative · entry 3 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,706 F2 · price: This transaction was executed in multiple trades at prices ranging from $62.12 to $63.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 13, 2018 Filed Mar 14, 2018 23:02 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 23,475 | $61.52 | $1,444,182.00 |
DisclosureSEC source: 0001144204-18-014729 · tv488500_form4.xml · nonDerivative · entry 2 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,231 F1 · price: This transaction was executed in multiple trades at prices ranging from $61.11 to $62.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 23:02 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Exercise / conversionStock Option · Derivative | 15,723 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001144204-18-014729 · tv488500_form4.xml · derivative · entry 5 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,723 shares Expires 2023-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options vested and become exercisable in equal annual amounts over a four-year period beginning on the first anniversary of the grant date. The grant date was July 12, 2013. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 23:02 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Exercise / conversionCommon Stock | 15,723 | $6.36 | $99,998.28 |
DisclosureSEC source: 0001144204-18-014729 · tv488500_form4.xml · nonDerivative · entry 1 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 22:00 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Exercise / conversionStock Option · Derivative | 8,236 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001144204-18-012823 · tv487707_form4.xml · derivative · entry 9 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,723 Underlying: Common Stock · 8,236 shares Expires 2023-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The options vested and become exercisable in equal annual amounts over a four-year period beginning on the first anniversary of the grant date. The grant date was July 12, 2013. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 22:00 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Exercise / conversionStock Option · Derivative | 6,375 | $0.00 Strike: $33.00 | $0.00 |
DisclosureSEC source: 0001144204-18-012823 · tv487707_form4.xml · derivative · entry 8 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,375 Underlying: Common Stock · 6,375 shares Expires 2024-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options vested and become exercisable in equal annual amounts over a four-year period beginning on the first anniversary of the grant date. The grant date was April 1, 2014. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 22:00 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Exercise / conversionStock Option · Derivative | 9,375 | $0.00 Strike: $40.59 | $0.00 |
DisclosureSEC source: 0001144204-18-012823 · tv487707_form4.xml · derivative · entry 7 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,125 Underlying: Common Stock · 9,375 shares Expires 2026-04-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options vest and become exercisable in equal annual amounts over a four-year period beginning on the first anniversary of the grant date. The grant date was April 7, 2016. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 22:00 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 4,260 | $62.17 | $264,844.20 |
DisclosureSEC source: 0001144204-18-012823 · tv487707_form4.xml · nonDerivative · entry 6 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,983 F3 · price: This transaction was executed in multiple trades at prices ranging from $62.00 to $62.525. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 22:00 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 8,400 | $61.62 | $517,608.00 |
DisclosureSEC source: 0001144204-18-012823 · tv487707_form4.xml · nonDerivative · entry 5 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,243 F2 · price: This transaction was executed in multiple trades at prices ranging from $61.00 to $61.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 22:00 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 11,326 | $60.59 | $686,242.34 |
DisclosureSEC source: 0001144204-18-012823 · tv487707_form4.xml · nonDerivative · entry 4 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,643 F1 · price: This transaction was executed in multiple trades at prices ranging from $60.00 to $60.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 22:00 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Exercise / conversionCommon Stock | 8,236 | $6.36 | $52,380.96 |
DisclosureSEC source: 0001144204-18-012823 · tv487707_form4.xml · nonDerivative · entry 3 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,969 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 22:00 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Exercise / conversionCommon Stock | 6,375 | $33.00 | $210,375.00 |
DisclosureSEC source: 0001144204-18-012823 · tv487707_form4.xml · nonDerivative · entry 2 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,733 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 22:00 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Exercise / conversionCommon Stock | 9,375 | $40.59 | $380,531.25 |
DisclosureSEC source: 0001144204-18-012823 · tv487707_form4.xml · nonDerivative · entry 1 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2017 Filed Jan 2, 2018 21:01 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GiftCommon Stock | 850 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-000204 · tv481995_form5.xml · nonDerivative · entry 1 PRZYBYL ARTHUR · CIK 0001268135 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,983 Read SEC document |
| May 22, 2017 Filed May 24, 2017 20:30 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 991 | $47.01 | $46,586.91 |
DisclosureSEC source: 0001144204-17-029342 · v467759_form4.xml · nonDerivative · entry 1 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,833 F1 · kind: In accordance with Rule 16b-3, represents shares withheld by the Issuer to satisfy tax withholding obligation upon vesting of a previously reported restricted stock award. Read SEC document |
| April 17, 2017 Filed Apr 18, 2017 20:33 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 1,161 | $51.22 | $59,466.42 |
DisclosureSEC source: 0001144204-17-020904 · v464426_4.xml · nonDerivative · entry 1 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,824 F1 · kind: In accordance with Rule 16b-3, represents shares withheld by the Issuer to satisfy tax withholding obligation upon vesting of a previously reported restricted stock award. Read SEC document |
| April 07, 2017 Filed Apr 11, 2017 20:34 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 1,451 | $51.24 | $74,349.24 |
DisclosureSEC source: 0001144204-17-020030 · v464045_form4.xml · nonDerivative · entry 1 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,985 F1 · kind: In accordance with Rule 16b-3, represents shares withheld by the Issuer to satisfy tax withholding obligation upon vesting of a previously reported restricted stock award. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 22:04 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantStock Options · Derivative | 47,500 | $0.00 Strike: $49.51 | $0.00 |
DisclosureSEC source: 0001144204-17-018956 · v463547_form4.xml · derivative · entry 4 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 47,500 shares Expires 2027-03-30 F1 · security: The restricted stock and the stock options vests in equal annual installments on the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 22:04 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 23,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-018956 · v463547_form4.xml · nonDerivative · entry 3 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,436 F1 · security: The restricted stock and the stock options vests in equal annual installments on the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| March 07, 2017 Filed Apr 4, 2017 22:04 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GiftCommon Stock | 560 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-018956 · v463547_form4.xml · nonDerivative · entry 2 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,686 Read SEC document |
| March 07, 2017 Filed Apr 4, 2017 22:04 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GiftCommon Stock | 560 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-018956 · v463547_form4.xml · nonDerivative · entry 1 PRZYBYL ARTHUR · CIK 0001268135 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,246 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.